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Introduction
Resolution of sister chromatid cohesion is a fundamental pro-
cess required for faithful chromosome segregation. Together 
with  cohesin-mediated  cohesion,  DNA  catenation  maintains 
chromosome cohesion in the early stages of mitosis (Díaz- 
Martínez et al., 2008; Yanagida, 2009). By the onset of ana-
phase, however, the cohesin complex is removed by separase 
through anaphase-promoting complex/cyclosome (APC/C)-
dependent ubiquitination and degradation of securin, and the 
catenation of centromeric DNA is resolved by the action of a 
specialized enzyme called DNA topoisomerase II (TopoII; 
Porter and Farr, 2004; Lee and Bachant, 2009). Several early 
studies showed that TopoII relocalizes from chromosome 
arms to the centromere during mitosis (Gorbsky, 1994; Ishida   
et al., 1994; Tavormina et al., 2002), and further studies using self-
primed in situ labeling revealed that catalytically active TopoII 
accumulates primarily at the centromere (Andersen et al., 2002).   
In addition, recent studies have shown that ultrafine bridges 
originating  from  tangled  DNA  in  metaphase  chromosomes 
were resolved by TopoII activity after removal of the cohesin 
complex (Wang et al., 2010), which indicates a role for TopoII 
activity in mitosis. This evidence strongly suggests tight regula-
tion of TopoII activity in space and time. Although extensive 
biochemical studies have elucidated the molecular mechanism 
of TopoII family proteins’ enzymatic reactions (Schoeffler and 
Berger, 2008), how the catalytic activity of TopoII is regulated 
at the centromere in such a specific manner is unknown.
Studies examining the relationship between TopoII ac-
tivity and posttranslational modification (PTM) have not clearly 
demonstrated that TopoII activity is regulated by PTM (Isaacs 
et al., 1998; Ishida et al., 2001). Yet, one PTM of TopoII, 
SUMOylation, has been suggested as a potential regulator of 
TopoII activity given that TopoII SUMOylation is mitosis 
specific and occurs near centromeres (Bachant et al., 2002). 
SUMO (small ubiquitin-like modifier) is a conserved ubiquitin 
family protein in eukaryotes (Johnson, 2004; Geiss-Friedlander 
and Melchior, 2007). Vertebrates typically express three SUMO 
paralogues designated as SUMO1, -2, and -3. SUMO2 and -3 
are 95% identical, whereas SUMO1 has 45% identity with 
both SUMO2 and -3. (In this paper, we refer to SUMO2 and -3 
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of TopoII and PIASy at centromeres and the stimulation of 
inhibitory SUMOylation at Lys660 by DNA binding of TopoII 
further suggest that this novel regulation of TopoII activity is 
controlled spatiotemporally during mitosis. Therefore, we propose 
that the SUMO ligase PIASy catalyzes SUMO2/3 modification 
of TopoII that regulates TopoII activity during mitosis.
Results
PIASy promotes SUMO2/3 conjugation of 
TopoII in XEEs
We previously demonstrated, using an XEE cell-free assay, that 
TopoII is modified by SUMO2/3 in a PIASy-dependent man-
ner (Azuma et al., 2005). More recently, studies in MEFs sug-
gested that RanBP2 promotes SUMOylation of TopoII through 
SUMO1 conjugation (Dawlaty et al., 2008). To investigate whether 
RanBP2 has a role in SUMOylation of TopoII in XEE assays, 
we immunodepleted XEE of specific E3 enzymes (RanBP2, 
PIASy, or RanBP2/PIASy) and examined TopoII for altera-
tions  in  SUMOylation.  After  immunodepletion  of  RanBP2 
from  XEE,  SUMO2/3  modification  was  still  intact  in  the 
chromosomal fractions (indicated by the bracket in Fig. 1 a).   
In contrast, no detectable TopoII SUMOylation was observed 
in the absence of PIASy (Fig. 1 a). The lack of SUMO1-modified   
proteins  associated  with  mitotic  chromosomes  indicates  that 
TopoII on mitotic chromosomes is exclusively modified by 
SUMO2/3 (Fig. 1 a).
We  further  analyzed  PIASy-dependent  SUMO2/3  modi-
fication  of TopoII  on  mitotic  chromosomes  by  immuno-
fluorescence microscopy. Using EGFP-fused SUMO2 in XEE 
assays, we previously showed that SUMO2/3-modified pro-
teins are localized on inner centromeric regions (Azuma et al.,   
2005). For the current study, we prepared an antibody to en-
able visualization of endogenous SUMO2/3 on chromosomes.   
Mitotic chromosomes prepared from replicated chromatin in 
XEE were fixed and immunostained using antibodies specific 
for TopoII, PIASy, and SUMO2/3 (Fig. 1 b). We observed that 
PIASy localizes to distinct foci on mitotic chromosomes, and these 
foci overlap with SUMO2/3 localization (Fig. 1 b). Because en-
dogenous SUMO2/3 also colocalizes with an inner centromeric 
marker, Aurora B (Fig. S1), we concluded that PIASy displays 
centromeric localization. Finally, we verified the localization 
of  TopoII  using  two  different  antibodies.  Both  antibodies 
revealed that TopoII is located throughout the chromosome 
axis, with clear accumulation at the centromeres of mitotic 
chromosomes as previously shown in other species (Fig. 1 b  
and Fig. S1; Gorbsky, 1994; Chang et al., 2003). Overall, the 
colocalization of TopoII and SUMO2/3 was clearly apparent 
at the centromeric regions but not in other parts of the chromo-
some, which suggests that SUMOylation of TopoII mainly 
occurs at the centromere and in proximity to PIASy (Fig. 1 b). 
The staining pattern of TopoII did not change after addi-
tion  of  dominant-negative  Ubc9  (dnUbc9),  which  prevents 
SUMOylation, indicating that localization of TopoII was not   
altered by the perturbation of SUMOylation (Figs. 1 b and S1). 
Because  we  found  no  evidence  for  RanBP2  involvement   
in SUMO2/3 modification of TopoII in our assay system,   
as SUMO2/3 when they are indistinguishable.) SUMO proteins   
contain a C-terminal di-glycine motif that is exposed by a hydro-
lase before a SUMOylation reaction of target proteins. The 
biochemical process of SUMOylation requires unique compo-
nents but is somewhat similar to the ubiquitination pathway. 
First, SUMO proteins are activated by the E1 enzyme (Aos1/
Uba2 heterodimer); then, they are transferred to the E2 enzyme 
(Ubc9) and finally conjugated to cellular substrates via an E3 li-
gase enzyme. Defects in the SUMOylation pathway have been 
found to cause faulty mitosis (Watts, 2007; Dasso, 2008), typically 
represented in most organisms by failure of proper chromosome 
segregation (Biggins et al., 2001; Hari et al., 2001; Nacerddine   
et al., 2005).
Siz1p and Siz2p, which are conserved eukaryotic SUMO 
E3 ligases, are responsible for the SUMOylation of TopoII in 
budding yeast, and the loss of Siz-mediated TopoII SUMOylation 
decreases chromosome transmission fidelity (Takahashi et al., 
2006). Using a Xenopus egg extract (XEE) cell-free assay, we 
previously showed that PIASy, a member of the PIAS/Siz family 
of SUMO ligases, is an essential chromosomal component for 
promoting TopoII SUMO2/3 modification in vertebrates, and 
suggested a role for PIASy in chromosome segregation (Azuma 
et al., 2005). Moreover, studies using HeLa cells revealed that 
PIASy is required for faithful chromosomal separation, which is 
not dependent on centromeric cohesin but is related to TopoII 
localization at the centromere (Díaz-Martínez et al., 2006).   
Together, this evidence indicates that the PIAS/Siz family of 
E3 ligases has a conserved role in chromosome segregation in   
eukaryotes through regulation of TopoII SUMOylation. In con-
trast, studies using lysates from mouse embryonic fibroblasts 
(MEFs) that were deficient in RanBP2/Nup358, a SUMO E3 ligase   
that is also a component of the nuclear pore complex in verte-
brates (Pichler et al., 2002), provided evidence that RanBP2 fa-
cilitates SUMOylation of TopoII through SUMO1 conjugation 
(Dawlaty et al., 2008). The discrepancy between these models 
remains to be examined.
For this paper, we established an in vitro SUMOylation 
assay using recombinant TopoII as substrate in order to elucidate 
the  biochemical  consequence  of  PIASy-mediated  SUMO2/3 
modification on TopoII activity. Consistent with our previous 
results using XEE assays (Azuma et al., 2005), we demonstrate 
that PIASy robustly facilitates SUMOylation of TopoII, and 
this modification is SUMO2/3 specific in vitro. We also observed 
that SUMOylated TopoII exhibits much less DNA decatenation 
activity, which indicates a potential mechanism for inhibition of 
TopoII activity by SUMOylation. Using mass spectrometric 
analysis  of TopoII  isolated  from  mitotic  chromosomes,  we 
identified lysine 660 (Lys660) as a novel SUMOylation site of 
TopoII. Further biochemical studies demonstrated that elimi-
nation of SUMOylation at Lys660 suppressed SUMOylation-
dependent inhibition of TopoII activity, independent of other 
SUMOylation  sites.  Finally,  we  show  that  SUMOylation  of 
Lys660 is stimulated by DNA binding of TopoII, which sug-
gests that the enzymatically active TopoII might be a primary 
target of Lys660 SUMOylation.
Our findings strongly suggest that TopoII SUMOylation 
regulates decatenation of centromeric DNA. The colocalization   785 SUMOylation-dependent inhibition of TopoII • Ryu et al.
SUMOylation of TopoII in an in vitro assay. For these studies, 
all of the protein components required for SUMOylation were 
prepared as described in Materials and methods. For most in vitro 
SUMOylation reactions, we used 500 nM of T7-tagged TopoII, 
5 µM SUMO, and 15 nM E1 (Aos1/Uba2), and the SUMOylation 
was detected by Western blotting using the T7 tag.
Ubc9, a SUMO E2 conjugating enzyme, directly binds to 
its consensus sequence on substrates without E3 ligase (Bernier-
Villamor et al., 2002; Geiss-Friedlander and Melchior, 2007), 
and, in fact, major SUMOylation sites of budding yeast TopoII 
were identified based on this consensus sequence (Bachant et al., 
2002). Hence, we sought to identify whether SUMOylation of 
Xenopus laevis TopoII is dependent on Ubc9. Purified X. laevis 
we  focused  our  subsequent  studies  on  PIASy-mediated 
TopoII SUMOylation.
PIASy promotes SUMO2/3 conjugation 
of TopoII in reconstituted in vitro 
SUMOylation assays
We previously demonstrated the requirement of PIASy activ-
ity for SUMOylation of chromosomal TopoII in XEE assays 
(Azuma et al., 2003). However, because of the extreme instabil-
ity of the SUMOylation reaction, experimentally managing the 
state of SUMOylation in vivo was difficult, limiting the use of 
XEE assays for further investigations of TopoII SUMOylation. 
Therefore, we next sought to examine the PIASy-dependent   
Figure 1.  PIASy but not RanBP2 is required for SUMO2/3 conjugation of TopoII in XEE. (a) XEE were immunodepleted using antibodies against RanBP2, 
PIASy, or RanBP2/PIASy. The depleted extracts were incubated with 10,000 sperm nuclei/µl for 1 h at 25°C. Non- or mock (IgG)-depleted extracts were 
also subjected to the same procedure. Isolated chromosomes from each reaction were analyzed by Western blotting (WB) for the indicated protein.   
Immunodepletion (ID) of RanBP2 had no effect on the SUMOylation of TopoII, whereas PIASy ID eliminated TopoII SUMOylation. The arrow and bracket 
indicate unmodified and SUMO2/3-modified TopoII, respectively. Positions of molecular mass standards (kD) are indicated on the left. (b) The mitotic 
chromosomes were prepared as in Materials and methods and were analyzed by immunostaining with the indicated antibodies: TopoII is shown in red, 
PIASy is shown in green, and SUMO2/3 is shown in blue in merged panel. TopoII colocalized with PIASy and SUMO2/3 at the centromeres. The addi-
tion of dnUbc9 eliminated SUMO2/3 modification but did not alter the localization of TopoII at the centromeres of mitotic chromosomes. Bars, 10 µm.JCB • VOLUME 191 • NUMBER 4 • 2010   786
activity of TopoII is markedly inhibited by SUMO conjugation 
(Fig. 3, b and c). One interesting aspect of this analysis is that, 
despite subtle differences in TopoII SUMOylation among the 
series of reactions, the presence of the highest molecular weight 
band (indicated by the arrow in Fig. 3 a) appeared to correlate 
with strong inhibition of TopoII decatenation activity. Together, 
our results indicate that PIASy-mediated SUMO modification of 
TopoII inhibits TopoII decatenation activity.
Lysine at 660 is one SUMOylation site of 
TopoII in XEE
To better understand the molecular basis of TopoII inhibition 
by SUMOylation, we sought to identify SUMOylation sites of 
TopoII. To this end, a SUMOylated form of endogenous TopoII 
was purified from mitotic chromosomes prepared in XEE (Fig. S2). 
Isolated bands were double-digested with trypsin and chymotrypsin 
followed by mass spectrometric analysis using the same method as 
used to identify the SUMOylation site of poly (ADP-ribose) poly-
merase I (PARP1), another mitotic chromosomal substrate (Ryu   
et al., 2010). Double digestion with trypsin and chymotrypsin gen-
erates a remnant of the SUMO sequence (QQQTGG, with a mass 
of 599.2663 D) on the lysine of a SUMO modified peptide. With 
50% sequence coverage, Lys660 (K*EWLTNFMQDR, where 
the asterisk refers to QQQTGG) was shown to have the SUMO 
signature in the digested pool of SUMO2/3-TopoII (Fig. S3). 
This result was unexpected given that (a) the sequences surround-
ing Lys660 do not match the canonical or noncanonical consensus 
sequences predicted using a SUMO prediction program (Xue et al., 
2006), and (b) the genetically determined SUMOylation sites in 
budding yeast were all located in the C-terminal domain (Bachant 
et al., 2002; Takahashi et al., 2006), whereas Lys660 is located in 
the core active domain (DNA gate) of TopoII (Fig. 4 a; Berger   
et al., 1996; Schoeffler and Berger, 2005). Also, it was striking that 
the sequences including and surrounding Lys660 are highly con-
served, from yeast to human (Fig. 4 a).
To confirm the mapping result, recombinant wild-type 
TopoII (WT) or TopoII with an arginine substitution for Lys660 
(K660R) were prepared as described in Materials and methods, and 
the purity of these recombinant proteins was confirmed, as shown 
in Fig. S4. Add-back experiments of the recombinant proteins to 
TopoII-immunodepleted XEE indicated that the K660R mutant 
exhibited a slight reduction in higher shifted species of SUMOylated 
TopoII compared with that of WT. Although major SUMOylations 
still occurred (Fig. 4, b and c) using both an untagged (Fig. 4 b) and 
T7-tagged (Fig. 4 c) recombinant TopoII, K660R showed a re-
producible deficiency in generating SUMOylation represented by 
higher shifted bands. In summary, Lys660 is a SUMOylation site of 
TopoII associated with mitotic chromosomes in XEE, and other 
SUMOylation sites remain to be identified.
Lack of TopoII SUMOylation at Lys660 
abolishes SUMOylation-dependent inhibition 
of TopoII activity
Available x-ray crystal structure information for TopoII indi-
cates that Lys660 faces DNA (Dong and Berger, 2007). There-
fore, we predicted that alteration of Lys660 would affect TopoII 
activity. Indeed, when we compared the decatenation activity of 
TopoII was incubated with various concentrations of Ubc9 and 
analyzed by Western blotting. Our results indicated that Ubc9 
could promote SUMOylation of TopoII in a dose-dependent 
manner (Fig. 2 a), and 300 nM Ubc9 was sufficient to promote 
SUMOylation of >50% of the TopoII. However, when the con-
centration of Ubc9 was close to the endogenous levels found in 
XEE, 30 nM, the efficiency of TopoII SUMOylation dropped 
to barely detectable levels (Fig. 2, a and b).
Next, to assess the contribution of PIASy to SUMOylation, 
TopoII was incubated with various concentrations of PIASy 
using a physiologically relevant concentration of Ubc9 (30 nM). 
Under such conditions, TopoII was efficiently SUMOylated in 
the presence of PIASy, and could be SUMOylated even when 
PIASy concentration was 10 nM, which is near the endogenous 
level in XEE (Fig. 2, c and d).
The observation that TopoII is specifically modified by 
SUMO2/3 in XEE led us to hypothesize that PIASy may select 
the SUMO paralogue for the conjugation. To test this hypothe-
sis, TopoII was incubated with either SUMO1 or SUMO2   
in the presence of PIASy and physiological concentrations of 
Ubc9. This assay revealed that PIASy mediates modification of 
TopoII by SUMO2 but not by SUMO1 (Fig. 2 e), even though 
SUMO1 was highly active with RanGAP1 as the substrate (not 
depicted), as previously shown (Azuma et al., 2001). This indi-
cates that PIASy plays a role in the selection of SUMO para-
logues. We also confirmed that PIASy mediates modification of 
TopoII with SUMO3 in similar level as with SUMO2 (unpub-
lished data). Together, we conclude that PIASy is an essential 
element for SUMO2/3 modification of TopoII under physio-
logical conditions.
PIASy-mediated SUMOylation inhibits the 
decatenation activity of TopoII
Previous studies in HeLa cells have suggested that PIASy is re-
quired for regulation of cohesin-independent cohesion of centro-
meres (Díaz-Martínez et al., 2006). We speculated that PIASy might 
play a role in localizing TopoII to the centromere by regulating its 
SUMOylation; however, we found that inhibition of SUMOylation 
did not alter TopoII localization in XEE assays (Fig. 1 b). There-
fore, we examined whether PIASy-dependent SUMOylation 
alters TopoII activity, which is required for proper chromosome 
segregation. To this end, TopoII was incubated in an in vitro 
SUMOylation reaction with either a processed form of SUMO2 
(SUMO2-GG) or a truncated form of SUMO2 (SUMO2-G)   
that cannot be conjugated to substrates because of a lack of one 
C-terminal glycine. SUMOylated and non-SUMOylated TopoII 
were then analyzed for decatenation activity using kinetoplast 
DNA (kDNA) as a substrate. Once decatenated by TopoII, the 
interlocking chain of circular kDNA releases to form minicircles. 
As shown in Fig. 3 a, TopoII was differentially SUMOylated in 
60 min in vitro using various concentrations of Ubc9 and PIASy 
in the presence of SUMO2-GG. A control reaction that con-
tained Ubc9 and PIASy in the presence of SUMO2-G showed no   
SUMOylation. Western blot analysis revealed that the intensity of 
TopoII SUMOylation could be controlled by the in vitro reac-
tion conditions and that >50% of the TopoII was modified under 
each condition. Subsequent assays indicated that the decatenation 787 SUMOylation-dependent inhibition of TopoII • Ryu et al.
Figure 2.  PIASy is required for the efficient SUMOylation of TopoII and for the selection of SUMO paralogues. (a) Ubc9 dosage-dependent SUMOylation. 
T7 tagged-TopoII was incubated in a reaction containing various concentrations of Ubc9 (0–300 nM) in the presence of SUMO2. The amount of SUMO2-
conjugated TopoII was similar to that seen in XEE only when 300 nM Ubc9 was added. (b) Time course experiment with physiological (30 nM) and higher 
(300 nM) concentration of Ubc9. (c) PIASy dosage-dependent SUMOylation. T7-TopoII was incubated as in panel a, except with various concentrations 
of PIASy (0–100 nM) and with the physiological concentration of Ubc9 (30 nM). PIASy efficiently facilitated SUMOylation of TopoII under conditions 
using 30 nM Ubc9, where SUMOylation had barely appeared in the absence of PIASy. SUMOylation was saturated using >60 nM PIASy. (d) Time course 
experiment of PIASy-dependent SUMOylation. The reactions were performed with physiological (10 nM) or higher (100 nM) concentrations of PIASy in 
the presence of 30 nM Ubc9. (e) T7-TopoII was incubated with either SUMO1 (s1) or SUMO2 (s2) in the presence of PIASy as indicated. PIASy showed 
a preference for SUMO2 over SUMO1. Positions of molecular mass standards (kD) are indicated on the sides of the gel blots.JCB • VOLUME 191 • NUMBER 4 • 2010   788
For SUMOylation reactions (Fig. 5, c and e), we used 60/30 nM of 
Ubc9/PIASy to better observe the inhibition of TopoII WT decat-
enation activity by SUMOylation and the potential alteration in the 
SUMOylation-dependent regulation of TopoII activity for the 
K660R mutant. Consistent with our earlier results, the decatena-
tion activity of TopoII WT was efficiently inhibited by SUMO 
modification (Fig. 5, d and g). However, it was striking that the 
decatenation activity of TopoII K660R was no longer inhibited 
by SUMO modification (Fig. 5, f and h), despite the fact that both 
TopoII WT (Fig. 5 c) and K660R mutant (Fig. 5 e) were robustly 
modified by SUMO2. Similar results were obtained using different 
recombinant, unSUMOylated WT and K660R TopoII, K660R 
was 20 times less active than WT (Fig. 5 a). Yet, gel mobility 
shift assays showed that both WT and K660R bind to DNA with 
similar affinity (Fig. 5 b), which suggests that lower decatena-
tion activity of K660R is not simply caused by the deficiency of 
DNA binding. Given that the relatively minor alteration, substi-
tuting Lys660 with arginine, reduces TopoII decatenation ac-
tivity, we speculated that SUMO conjugation of Lys660 might 
have a significant impact on the activity of TopoII.
To  test  this,  TopoII  WT  and  K660R  were  applied   
to  the  in  vitro  SUMOylation–decatenation  coupled  assay. 
Figure 3.  SUMO modification affects the de-
catenation  activity  of  TopoII.  (a)  T7-TopoII 
was incubated with various combinations of 
Ubc9/PIASy as indicated to obtain a series 
of SUMOylation profiles. All control reactions 
(Cont.)  were  performed  with  60  nM  Ubc9/ 
10 nM PIASy and SUMO2-G, which could not 
be conjugated. The samples were analyzed by 
Western blotting for the T7 tag. The arrow indi-
cates maximal SUMO modification of TopoII 
(seen in 30/30 and 60/10). Positions of mo-
lecular mass standards (kD) are indicated on 
the right. (b) Representative data of decatena-
tion  assay.  Samples  in  a  were  further  incu-
bated with decatenation buffer that contained 
kDNA  for  10  or  20  min,  and  the  products 
were resolved in an agarose gel. Decatenated 
and  linearized  markers  are  designated.   
(c) Band intensity data from five independent 
experiments performed as in b are presented 
as the percentage of catenated kDNA remain-
ing after a 20-min incubation, with standard 
error (error bars) and probability value from 
a  Student’s  t  test.  SUMO2  modification  of 
TopoII decreased its decatenation activity.789 SUMOylation-dependent inhibition of TopoII • Ryu et al.
We  speculated  that  this  limited  accessibility  might  corre-
late with our inability to see a dramatic difference in the in vitro   
SUMOylation profile of WT and K660R TopoII, even though 
we observed subtle but reproducible reduction of K660R TopoII 
SUMOylation in XEE assays (Fig. 4, b and c). We suspected that 
when TopoII binds to DNA, it changes conformation, making it 
susceptible to SUMOylation of Lys660 in the XEE assay. To ex-
amine this hypothesis, we performed in vitro SUMOylation assays 
with WT TopoII in the presence or absence of DNA. As shown   
tagged TopoII WT and K660R for the analysis (Fig. S5). These 
results suggest that PIASy-mediated SUMOylation on Lys660 has 
a crucial role in the regulation of TopoII activity.
SUMOylation of TopoII Lys660 is 
regulated by DNA
Based on x-ray crystallographic structure analysis, TopoII 
Lys660 lies near the DNA backbone and appears not eas-
ily accessible for SUMOylation (Dong and Berger, 2007). 
Figure 4.  TopoII K660R, a candidate SUMOylation mutant, shows incomplete SUMOylation in XEE. (a) Schematic diagram of S. cerevisiae TopoII 
primary structure. Domains are denoted by color. This panel was modified from Schoeffler and Berger (2008), with permission from Cambridge University 
Press. TOPRIM, Topoisomerase-primase fold domain; WHD, Winged-helix domain; Tower, adjacent domain to WHD. The black bar indicates the catalytic 
tyrosine (Y782) for DNA cleavage in the WHD domain. Lys660 in X. laevis TopoII was designated as a potential SUMOylation site by mass spectrometric 
analysis. The approximate position of the candidate lysine is shown by a green star in the DNA gate domain of TopoII. The sequences near TopoII Lys660 
from X. laevis (xl), Homo sapiens (hs), and S. cerevisiae (sc) are conserved (indicated with bold and underlined text). (b) XEE were immunodepleted using 
nonspecific IgG (Cont.) or an anti-TopoII antibody (Topo). Efficiency of TopoII depletion was confirmed by comparison of mock-depleted (Cont.) to 
TopoII-depleted (Topo) CSF extracts (left two lanes, labeled CSF extracts). WT nontagged TopoII (WT) or mutant TopoII, with substitution of arginine for 
Lys660 (K660R), was added to the TopoII-depleted extracts (Topo). After 1 h incubation at 25°C, mitotic chromosomes were isolated and analyzed by 
anti-TopoII Western blotting. Analyzed chromosome samples were from mock-depleted (Cont.), TopoII-depleted (Topo), and recombinant TopoII added-
back extracts (Topo+WT or –Topo+K660R). (c) Same examination as in b except that the recombinant TopoII proteins had a T7 tag at the N terminus. 
Both nontagged and T7-tagged K660R mutant showed subtle but reproducible reduction in higher shifted bands (indicated by brackets) of SUMOylation 
compared with WT. Positions of molecular mass standards (kD) are indicated on the sides of the gel blots.JCB • VOLUME 191 • NUMBER 4 • 2010   790
significant difference in the SUMOylation profile between WT and 
K660R in the absence of DNA (Fig. 6 b). Considering the compa-
rable DNA binding affinity of both proteins (Fig. 5 b), it is therefore 
reasonable to conclude that the alteration of TopoII conformation 
by DNA binding (Berger et al., 1996; Roca et al., 1996; Dong and 
Berger, 2007) increases the efficiency of TopoII SUMOylation. 
Together, our results suggest that there are SUMOylation sites 
of TopoII whose availability for SUMOylation depends on the 
conformational change of TopoII resulting from DNA binding, 
and that the SUMOylation of Lys660, which plays a key role in   
SUMOylation-dependent TopoII inhibition, is one of those sites.
Discussion
Our central achievement here is the finding of SUMOylation- 
dependent regulation of TopoII activity. We previously found 
that SUMOylation of TopoII did not significantly alter its   
in Fig. 6 a, WT TopoII was extremely susceptible to SUMOylation   
in the presence of DNA. Addition of DNA to the in vitro reac-
tion increased the amount of TopoII SUMOylation as well as the 
rate of modification, such that the amount of SUMOylated WT 
TopoII after 1 h of incubation without DNA was comparable 
to that formed after 10 min with DNA (Fig. 6 a). Because both 
TopoII and PIASy can bind DNA, we also considered the pos-
sibility that DNA acts as an adaptor to increase the binding affinity 
of TopoII and PIASy, leading to acceleration of SUMOylation. 
However, because the SUMOylation of PARP1, another chromo-
somal substrate of SUMO2/3 found in XEE (Ryu et al., 2010), is 
barely affected by the addition of an equivalent amount of DNA 
(Fig. 6 b), this possibility seems unlikely, which supports the idea 
that DNA-dependent enhancement of TopoII SUMOylation re-
sults from exposure of SUMOylation sites by DNA binding. Re-
markably, we found that the K660R mutant displayed a reduction 
of SUMOylation in the presence of DNA, although there was no 
Figure 5.  The elimination of TopoII SUMOylation at Lys660 blocks SUMOylation-dependent inhibition of TopoII activity. (a) Unmodified TopoII WT 
and K660R proteins were incubated with kDNA to determine relative activity. K660R had 20 times less activity than WT. (b) Electrophoretic mobility shift 
assay. Unmodified TopoII WT and K660R were incubated with plasmid DNA to determine relative DNA binding affinity. Both WT and K660R displayed 
similar binding affinity to DNA. oc and cc stand for open and closed circle, respectively. (c and e) The TopoII WT and K660R were SUMO2-modified 
in vitro with 60 nM of Ubc9 and 30 nM of PIASy. Control reactions (Cont.) using the same condition except for SUMO2-G were also performed. Non-
SUMOylated or SUMOylated TopoII samples were assayed for decatenation activity. (d and f) Representative results of decatenation activity assays with 
TopoII WT (d) and K660R (f) are shown. The mean decatenation activity from five independent experiments with TopoII WT (g) and four independent 
experiments with TopoII K660R (h) are displayed as the percentage of catenated kDNA remaining, with standard error (error bars). The strong inhibition 
of TopoII decatenation activity by SUMOylation was abolished in reactions using TopoII K660R. Positions of molecular mass standards (kD) are indicated 
on the sides of the gel blots.791 SUMOylation-dependent inhibition of TopoII • Ryu et al.
selection under these conditions were different from TopoII 
SUMOylation in XEEs. There are several other findings that 
argue against a role of RanBP2 as the primary E3 enzyme for 
TopoII in mitosis: First, the addition of Nocodazole, which 
disrupts the localization of RanBP2 from the centromere (Joseph 
et al., 2002), does not eliminate SUMOylation of TopoII 
(Azuma, 2009). Second, although Dawlaty et al. (2008) found 
that  RanBP2  promotes  SUMO1  conjugation  of  TopoII, 
TopoII is exclusively conjugated to SUMO2/3 in XEEs unless 
ectopic SUMO1 is supplied (Azuma et al., 2003). Finally, we 
observed that SUMO2/3 modification of TopoII on mitotic 
chromosomes was intact in RanBP2-immunodepleted XEEs   
unless PIASy was co-depleted (Fig. 1 a), which strongly sug-
gests  that  RanBP2  is  dispensable. Additionally,  endogenous 
TopoII, PIASy, and SUMO2/3 colocalized at the centromeres 
of mitotic chromosomes (Fig. 1 b), which is consistent with the 
notion that PIASy is the E3 enzyme for TopoII SUMOylation 
at this site. In contrast, RanBP2 localizes to the outer kinetochore   
enzymatic  activity  when  using  TopoII-containing  fractions 
from XEE (Azuma et al., 2003). However, we anticipated a 
potential role for SUMOylation in the regulation of TopoII 
activity based on the difficulty separating SUMOylated TopoII 
associated with centromeres from unSUMOylated TopoII asso-
ciated with other chromosome regions. The in vitro SUMOylation 
assay established for the current study allowed us to overcome 
the time and space obstacles of SUMOylation of TopoII, and 
thus to reexamine the possible role of SUMOylation in regulating 
TopoII activity during mitosis. Our assay clearly reveals that 
SUMOylation significantly inhibits the decatenation activity of 
TopoII and that this inhibition is correlated with the TopoII 
SUMOylation profile. In other words, the existence of the highest 
shifted species of SUMOylated TopoII, which appear when rel-
atively high concentration of enzymes (Fig. 3 a) or DNA are 
added to the reactions (Fig. 6 a), correlates with strong inhibi-
tion of TopoII activity.
The identification of Lys660 as a SUMOylation site fur-
ther supports the premise that TopoII activity is SUMOylation 
dependent. Lys660 is located within the DNA gate, which plays 
a key role in manipulation of double helical DNA strands (Dong 
and Berger, 2007; Schoeffler and Berger, 2008). Considering 
the importance of this region for TopoII function, it was pre-
dictable that even slight alteration of Lys660 would impact the   
activity of TopoII. Supporting this idea, replacement of Lys660   
with arginine resulted in a substantial reduction of the TopoII 
decatenation activity (Fig. 5 a), although no loss of DNA binding 
is observed (Fig. 5 b). Notably, the abolition of SUMO modifica-
tion at Lys660 eliminated the SUMOylation-dependent inhibi-
tion of TopoII decatenation activity. The interpretation of this   
result is obviously limited by the lower catalytic activity of the   
Lys660 mutant, which might render partial inhibition caused 
by SUMOylation of other sites of TopoII imperceptible. 
Therefore, detailed kinetic analyses of TopoII reactions, com-
bined with analysis of other currently unidentified SUMOylation 
sites, will be necessary to clarify the function of each TopoII  
SUMOylation site.
We  further  observed  that  Lys660  SUMOylation  is  en-
hanced in the presence of DNA, and this is likely caused by ex-
posure of the Lys660 site during the catalytic action of TopoII 
(Fig. 6 b). The hypothesis that an active TopoII conformation 
makes Lys660 more susceptible to SUMOylation is supported 
by an earlier finding that etoposide (or VP16) treatment of   
human cells induces hyper SUMOylation of TopoII at the centro-
mere (Agostinho et al., 2008). Etoposide immobilizes TopoII 
in an intermediate structure with cleaved DNA (Baldwin and 
Osheroff, 2005), thus potentially exposing a SUMOylation site, 
as shown in Fig. 6. Collectively, our results strongly suggest 
that SUMOylation of Lys660 is responsible for the control of 
decatenation activity. However, it is possible that other TopoII 
SUMOylation sites contribute to changes in TopoII activity.
The internal repeat (IR) domain of RanBP2 possesses 
SUMO E3 ligase activity in vitro, and studies in RanBP2- 
deficient MEFs have implicated RanBP2 in SUMO1 conjugation 
of TopoII (Dawlaty et al., 2008). We found that the IR domain 
of RanBP2 could enhance TopoII SUMOylation in vitro (un-
published data), but paralogue specificity and SUMOylation site 
Figure 6.  DNA binding of TopoII increases susceptibility of SUMOylation 
at Lys660. (a) TopoII WT in vitro SUMOylation reactions were performed 
with or without DNA. The samples were analyzed with anti-T7 tag anti-
body Western blots. The presence of DNA in the SUMOylation reactions 
significantly  stimulates  TopoII  WT  SUMOylation.  (b)  TopoII  WT  and 
TopoII K660R were subjected to in vitro reactions under the same condi-
tion as in a except for using 5 ng/µl of DNA. PARP1, a mitotic chromo-
somal SUMO2/3 substrate, was used as a control. A deficiency of TopoII 
K660R SUMOylation was observed in the presence of DNA compared 
with TopoII WT. Positions of molecular mass standards (kD) are indicated 
on the left.JCB • VOLUME 191 • NUMBER 4 • 2010   792
phenotypes  caused  by  SUMOylation-deficient  TopoII  and 
an examination of specific deSUMOylation mechanisms of 
TopoII will strengthen the functional significance of SUMO-
modified TopoII.
Materials and methods
DNA subcloning, site-directed mutagenesis, recombinant protein 
expression and purification, and antibodies
The cDNA of TopoII was cloned from X. laevis tadpole cDNA (provided 
by T. Amano and Y.B. Shi, National Institute of Child Health and Human 
Development, Bethesda, MD) using PCR amplification. The X. laevis TopoII 
coding sequence was subcloned into a pPIC 3.5 Kb vector in which either 
calmodulin-binding protein (CBP)-ZZ, CBP-T7, or T7-ZZ tag sequences were 
inserted (the CBP and ZZ TAP tag plasmids were provided by H. Yoon and 
K. Gould, Vanderbilt University, Nashville, TN). The lysine-to-arginine sub-
stitution of TopoII was generated by site-directed mutagenesis using a 
QuikChange kit (Agilent) according to manufacturer’s instructions. All con-
structs were verified by DNA sequencing.
For preparation of recombinant TopoII proteins, the plasmids were 
transformed into the GS115 strain of Pichia pastoris yeast and expressed ac-
cording to the manufacturer’s instructions (Invitrogen). Protein purification with 
the CBP and ZZ tags was performed using a modified TAP protocol (EMBL 
Heidelberg). In brief, yeast cells expressing TopoII were frozen and ground 
with dry ice in a coffee mill, then mixed with lysis buffer (50 mM Tris-HCl,   
pH 7.5, 150 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 0.1% Triton X-100,   
5% glycerol, 1 mM DTT, and 10 mM PMSF). Samples were then centrifuged at 
25,000 g for 40 min. To capture the CBP-tagged TopoII, the supernatant was 
mixed with calmodulin-sepharose resin (GE Healthcare) for 90 min at 4°C. 
The resin was then washed with lysis buffer, and TopoII was eluted with buffer 
containing 10 mM EGTA. For ZZ-tagged TopoII, proteins were captured on 
IgG-Sepharose (GE Healthcare), and elution was performed by cleaving with 
PreScission Protease (GE Healthcare) according to the manufacturer’s instruc-
tions. The elution was further purified by Mono Q anion-exchange chromatog-
raphy (GE Healthcare). The E1 complex (Aos1/Uba2 heterodimer; expression 
plasmids were provided by F. Melchior, Zentrum für Molekulare Biologie der 
Universität Heidelberg/Heidelberg University), PIASy, Ubc9, dnUbc9, and 
SUMO paralogues were expressed in BL21(DE3) or Rosetta(DE3) bacteria 
and purified as described previously.
Anti-TopoII/ monoclonal antibody was obtained from the Marine 
Biological Laboratory. Anti-SUMO2/3 polyclonal antibody was generated 
in guinea pigs (Azuma et al., 2003), and the polyclonal antibody against 
TopoII, C terminus (aa 1358–1579), was prepared in rabbits by injection 
with a recombinant His-T7 fused fragment, and was then affinity purified 
(Azuma et al., 2005). The anti-PIASy antibody used in this study has been 
described previously (Azuma et al., 2005).
(Joseph et al., 2002). It is possible that the discrepancy between 
findings in XEEs and MEFs simply reflects the difference in 
experimental systems, and that different SUMO ligases mediate 
TopoII conjugation in mice and frogs. Alternatively, we have 
recently shown that centromeric SUMOylation results from pre-
cise localization of PIASy and its substrates (Ryu and Azuma, 
2010). RanBP2 might indirectly affect the SUMOylation of 
TopoII by regulating the localization of TopoII to centromeres 
in MEFs through a mechanism that is not used in XEEs. The fail-
ure to localize TopoII could thus impair its subsequent PIASy- 
dependent SUMO2/3 modification.
Our findings that (a) PIASy colocalizes with TopoII at 
the centromere, where enzymatically active TopoII is thought 
to accumulate (Andersen et al., 2002); (b) the DNA-bound form 
of TopoII is more susceptible to SUMOylation on Lys660; 
and (c) the SUMOylation of Lys660 inhibits TopoII activ-
ity lead us to propose that PIASy-dependent SUMOylation 
of TopoII regulates centromeric catenation. In this model, 
when SUMOylation is depressed, overly active TopoII leads 
to DNA recatenation at the centromeres, where sister chroma-
tids are highly compact and close to each other. With proper 
SUMOylation, active TopoII is rendered temporarily inert to 
prevent recatenation (Fig. 7 a), and so only the proper amount 
of catenated DNA remains, avoiding early disjunction of sister 
chromatids before anaphase. This model explains why the per-
turbation of SUMOylation by either the elimination of PIASy 
or addition of dnUbc9 causes abnormal chromosomal segrega-
tion as represented by anaphase bridges, which could be the 
result of hypercatenation of centromeric DNA (Azuma et al., 
2003, 2005). The model also explain why depletion of PIASy 
in HeLa cells produces cohesin-independent sister chromatid 
cohesion (Díaz-Martínez et al., 2006).
There are several pieces of evidence that support a re-
quirement of TopoII activity for proper anaphase execution. 
According to a recent study of PICH (Plk1-interacting check-
point helicase)-positive DNA threads, centromeric DNA catena-
tion was resolved at the onset of anaphase (Wang et al., 2008). 
Wang et al., (2010) also demonstrated that TopoII decatenates 
centromeric DNA after removal of the cohesin complex. Lastly, 
TopoII SUMOylation is highly dynamic, with TopoII heav-
ily modified by SUMO during metaphase and the rapid dis-
appearance of modified TopoII at the onset of anaphase (Azuma   
et al., 2003). In this context, it is possible that deSUMOylation 
of TopoII regulates the timing of resolution of the catenated 
DNA at the centromere at the onset of anaphase. At anaphase, 
when the centromeres of sister chromatids are distal enough, de-
SUMOyation of TopoII allows the preferential decatenation of 
the last tangled sister chromatids. As such, we further propose 
that deSUMOylation of TopoII is critical to control the timing 
of the final decatenation at anaphase (Fig. 7 b). Extensive analy-
sis using specific deSUMOylation enzymes of TopoII must be 
performed to directly test this hypothesis.
In summary, our finding that TopoII activity is inhib-
ited by PIASy-mediated SUMOylation allows us to answer a 
long-standing question of how the catalytic activity of TopoII 
is tightly regulated in a space- and time-dependent manner. 
Future studies using somatic cells to observe consequential 
Figure 7.  Implications of SUMOylation in regulating the resolution of cen-
tromeric DNA. (a) Regulating the amount of catenated centromeric DNA. 
Active TopoII resolves catenated DNA at the centromere and SUMOylation 
reduces the activity of TopoII that has completed the decatenation of DNA. 
Without SUMOylation, overly active TopoII could recatenate DNA at the cen-
tromere. (b) Regulation of the timing of decatenation. TopoII SUMOylation 
keeps centromeric TopoII temporally inert until anaphase, when decatena-
tion of centromeric DNA must take place. Without proper deSUMOylation of 
TopoII, decatenation of centromeric DNA will be compromised.793 SUMOylation-dependent inhibition of TopoII • Ryu et al.
25°C, the non-SUMOylated and SUMOylated samples were further in-
cubated with 6.2 ng/µl of kDNA (TopoGEN, Inc.) in decatenation buffer 
at 25°C for the indicated time periods. Decatenation buffer consisted of   
50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 5 mM MgCl2, 0.5 mM DTT,   
30 µg BSA/ml, and 2 mM ATP. The reactions were stopped by adding one 
third volume of 6× DNA dye (30% glycerol, 0.1% SDS, 10 mM EDTA, and 
0.2 µg/µl bromophenol blue), and samples were loaded on a 1% agarose 
gel and electrophoresed at 100 V in TAE buffer (Tris-acetate-EDTA) until the 
samples reached the middle of the gel. The amount of kDNA remaining 
in the wells was measured using an Image Station 4000R (Kodak), and 
standard error was calculated using KaleidaGraph (Synergy Software).
Electrophoretic mobility shift assay
The assay was performed as described previously (Walker et al., 2004), 
with slight modifications. In brief, various amounts of TopoII WT and 
K660R (as indicated in Fig. 5 b) were incubated with 90 ng of pBS KS(+) 
DNA for 5 min at 25°C. In vitro SUMOylation reaction buffer was used 
as the reaction buffer in these assays to keep protein–DNA binding condi-
tions similar to those used in in vitro SUMOylation reactions. The reactions 
were stopped by adding one half volume of loading buffer (50% glycerol,   
10 mM EDTA, and 0.2% Bromophenol blue), and the samples were sub-
jected to electrophoresis at 40 V for 2 h at 4°C in a 1% agarose gel 
containing ethidium bromide. The DNA was documented using an Image 
Station 4000R.
Online supplemental material
Fig.  S1  shows  colocalization  of  TopoII  with  Aurora  B  regardless  of 
SUMOylation.  Fig.  S2  shows  the  isolated  endogenous  TopoII  from   
mitotic  chromosomes  that  were  subjected  to  analysis  of  SUMOylation 
sites.  Fig.  S3  shows  the  result  of  LC-MS/MS  analysis  of  SUMOylated 
TopoII,  which  indicates  Lys  660  as  the  candidate  SUMOylation  site. 
Fig. S4 shows the purified recombinant TopoII proteins that were used 
in this study. Fig. S5 shows the decatenation assays with the recombinant 
TopoII proteins that were purified using a CBP tag and ZZ tag affinity 
column.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.201004033/DC1.
We appreciate the gifts of anti-Aurora B antibody from A. Arnaoutov and   
M. Dasso, the X. laevis cDNA from T. Amano and Y. Shi, the CBP-ZZ TAP-tag 
plasmid from H. Yoon and K. Gould, and plasmids for E1 expression from 
F. Melchior. We thank K. L. Neufeld (University of Kansas), A. Arnaoutov, 
and M. Dasso for critical reading of this manuscript and for providing edito-
rial assistance. We thank to Ms. L. J. Embree (National Cancer Institute) for 
editorial assistance.
M. Furuta was supported as a Japan Society for the Promotion of Sci-
ence Research Fellow in Biomedical and Behavioral Research at the National 
Institutes of Health. This project was supported in part by a start-up grant 
from the Department of Molecular Biosciences at the University of Kansas and 
National Institutes of Health/National Center for Research Resources, Center 
For Cancer Experimental Therapeutics at the Centers of Biomedical Research 
Excellence (CCET-COBRE; P20 RR015563), and is currently supported by 
National Institutes of Health/National Institute of General Medical Sciences 
grants GM80278 and GM67945 (to S.P. Gygi).
Submitted: 7 April 2010
Accepted: 13 October 2010
References
Agostinho, M., V. Santos, F. Ferreira, R. Costa, J. Cardoso, I. Pinheiro, J. Rino, 
E. Jaffray, R.T. Hay, and J. Ferreira. 2008. Conjugation of human topo-
isomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to 
topoisomerase inhibitors: cell cycle stage and chromosome domain specific-
ity. Cancer Res. 68:2409–2418. doi:10.1158/0008-5472.CAN-07-2092
Andersen, C.L., A. Wandall, E. Kjeldsen, C. Mielke, and J. Koch. 2002. Active, 
but not inactive, human centromeres display topoisomerase II activity   
in vivo. Chromosome Res. 10:305–312. doi:10.1023/A:1016571825025
Arnaoutov, A., and M. Dasso. 2003. The Ran GTPase regulates kinetochore 
function. Dev. Cell. 5:99–111. doi:10.1016/S1534-5807(03)00194-1
Azuma, Y.  2009.  Analysis  of  SUMOylation  of  topoisomerase  IIalpha  with 
Xenopus egg extracts. Methods Mol. Biol. 582:221–231. doi:10.1007/ 
978-1-60761-340-4_17
Azuma, Y., S.H. Tan, M.M. Cavenagh, A.M. Ainsztein, H. Saitoh, and M. Dasso. 
2001. Expression and regulation of the mammalian SUMO-1 E1 enzyme. 
FASEB J. 15:1825–1827.
XEEs, immunodepletion, and add-back assays
Sperm nuclei and low-speed extracts of X. laevis eggs arrested in metaphase 
by cytostatic factor (CSF) were prepared according to standard protocols 
(Kornbluth et al., 2001; Azuma, 2009). Immunodepletion was performed 
as described previously with protein A–conjugated magnetic beads (Dynal;   
Arnaoutov and Dasso, 2003). For add-back experiments, the purified re-
combinant TopoII proteins were added to the immunodepleted extracts at 
a final concentration of 300 nM, which is comparable to the concentra-
tion of endogenous TopoII measured by quantitative Western blotting. 
Chromosome isolation and analysis of SUMOylation were performed as 
described previously (Azuma, 2009). In brief, mitotic chromosomes were 
prepared by incubating sperm nuclei with CSF-XEE at the final concentra-
tion of 5,000 sperm nuclei/µl at room temperature. After observation of 
assembly of mitotic chromosome, which takes an 45–60-min incubation, 
chromosomal fractions were isolated from XEE by centrifugation through a 
40% glycerol cushion at 10,000 g for 5 min at 4°C. The precipitated chromo-
somes were boiled in SDS-PAGE sample buffer, and the extracted proteins 
were resolved in 8–16% gradient SDS-PAGE gel followed by Western blot-
ting analysis with the indicated antibodies.
Immunofluorescence
The mitotic chromosomes for immunofluorescence analysis were prepared as 
described previously (Arnaoutov and Dasso, 2003). In brief, CSF extracts 
were driven into interphase by 0.6 mM CaCl2. 500 sperm/µl was incubated 
with the interphase extracts for 60 min at 23°C to allow for complete DNA 
replication. Then, a volume of fresh CSF extract equal to half of the original 
volume was added to induce mitosis. For inhibition of mitotic SUMOylation, 
dnUbc9 was added just before induction of mitosis, at a final concentration of 
150 ng/µl. After a 30-min incubation, the reactions were diluted threefold and 
fixed with PFA at a final concentration of 2%. The samples were spun onto 
coverslips through a 35% glycerol cushion, postfixed in 1.6% PFA, and ana-
lyzed  by  immunostaining  using  antibodies  against  TopoII  (either  mouse 
monoclonal or rabbit polyclonal), SUMO2/3 (guinea pig polyclonal), PIASy 
(rabbit polyclonal), and Aurora B (rabbit polyclonal; A. Arnaoutov and   
M. Dasso, National Institute of Child Health and Human Development/ 
National Institutes of Health). Anti–rabbit Alexa Fluor 568, anti–guinea pig   
Alexa Fluor 684, and anti–mouse Alexa Fluor 488 were used as secondary 
antibodies. DNA was counterstained by Hoechst 33342 (EMD) and samples 
were  mounted  in  Vectashield  medium  (Vector  Laboratories).  Specimens 
were observed using Volocity Imaging Software (PerkinElmer) on a micro-
scope (TE2000-U; Nikon) with a Plan-Apochromat 100×/1.40 NA objec-
tive lens, and images were taken with a Retiga SRV charge-coupled device 
camera (QImaging) at room temperature. Photoshop and Illustrator software 
(Adobe) were used for processing the obtained images to intensities and sizes 
according to JCB policy.
Purification of SUMOylated TopoII from mitotic chromosomes
After mitotic chromosomes were assembled and isolated from CSF extracts, 
chromosomal proteins were subsequently extracted by boiling the chromo-
some fractions with SDS-PAGE sample buffer. Immunoprecipitation was per-
formed on extracted denatured proteins as described previously (Kane et al., 
2002) using affinity-purified anti-TopoII antibody that had been covalently 
cross-linked to protein A Dynabeads (Invitrogen) by dimethyl pimelimidate 2 
HCl (Thermo Fisher Scientific). Isolated proteins were separated on 8–16% 
Tris-HCl gradient gels (Invitrogen) by SDS-PAGE, and visualized by silver stain-
ing (Owl kit; Daiichi). For liquid chromatography tandem mass spectrometry 
(LS-MS/MS) analysis, the isolated proteins were stained with CBB-R250.
In vitro SUMOylation assays
SUMOylation reactions were incubated at 25°C for 1 h unless otherwise 
indicated. SUMO2 was used in most of reactions except where noted. The 
reactions contained 15 nM E1, 5 µM SUMO2-GG, 500 nM T7-tagged 
TopoII, 2.5 mM ATP, and various concentrations of Ubc9 and PIASy as 
indicated in Fig. 5. Reaction buffers were composed of 20 mM Hepes,   
pH 7.8, 100 mM NaCl, 5 mM MgCl2, 0.05% Tween 20, 5% glycerol,   
1  mM  4-(2-aminoethyl)  benzenesulfonyl  fluoride  hydrochloride  (AEBSF), 
and 1 mM DTT. The reactions were stopped with half volumes of 3× SDS-
PAGE sample buffer, and the samples were resolved on 8–16% Tris-HCl 
gradient gels by SDS-PAGE, then analyzed by Western blotting with HRP-
conjugated anti-T7 monoclonal antibody (EMD).
In vitro SUMOylation–decatenation coupled assays
These assays were performed with 60 nM Ubc9 and 30 nM PIASy together 
with  other  protein  components  as  described  in  “In  vitro  SUMOylation   
assays.” A control was performed under the same conditions except that 
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